Scarica l'app Stockscreener
1.31
0.77%
0.01
Dopo l'orario di chiusura:
1.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.30
Aprire:
$1.29
Volume 24 ore:
265.03K
Relative Volume:
0.32
Capitalizzazione di mercato:
$65.08M
Reddito:
$300.00K
Utile/perdita netta:
$-27.61M
Rapporto P/E:
-2.2676
EPS:
-0.5777
Flusso di cassa netto:
$-22.17M
1 W Prestazione:
-3.68%
1M Prestazione:
-10.27%
6M Prestazione:
-53.71%
1 anno Prestazione:
+61.47%
Intervallo 1D:
$1.28
$1.33
Intervallo di 1 settimana:
$1.2101
$1.37
Portata 52W:
$0.7708
$3.82
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.31 | 73.03M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-08 | Iniziato | Raymond James | Outperform |
| 2026-06-05 | Iniziato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Oppenheimer | Outperform |
| 2025-10-17 | Iniziato | Leerink Partners | Outperform |
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
Mostra tutto
iBio Inc Borsa (IBIO) Ultime notizie
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ibio Stock Price Forecast. Should You Buy IBIO? - StockInvest.us
iBio, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - Kalkine
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
iBio Q2 EPS Forecast Decreased by Brookline Capital Markets - MarketBeat
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - Yahoo Finance
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportWyckoff Distribution - dars.gov.et
B. Riley Securities Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6 - Moomoo
iBio Advances IBIO-600 Through First Phase 1 Dose Escalation As Cash And Investments Reach $88 Million - Pulse 2.0
iBio, Inc. Revenue Breakdown – NASDAQ:IBIO - TradingView
iBio FY2026 Net Loss Widens to $33M on Higher R&D Spending - Minichart
iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary - TradingView
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Canada
IBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Moomoo
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
IBIO: Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028 - TradingView
iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
iBio reports FY2026 net loss of $33.0M, revenue $0.1M and $88.0M cash and investments - TradingView
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
iBio Reports Fiscal 2026 Financial Results and Corporate Update Highlighting Clinical and Pipeline Progress - Quiver Quantitative
IBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - marketscreener.com
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136% - scanx.trade
iBio (IBIO) Expected to Release Quarterly Earnings on Friday - MarketBeat
iBio (NYSE: IBIO) seeks 500M shares, revises equity plan for warrants - Stock Titan
iBio (IBIO) Chart: Closes 1.72% Lower at $1.43 for the Current Session; Current Setup: the Near-Term Reference Band Stretches From $1.36 to $1.50 in the Available RecordMax Pain Level - vinanet.vn
iBio Inc. (IBIO) Edges Higher Amid Biotech Sector Volatility: Key Levels to WatchAAII Neutral - vinanet.vn
Molly Carr Net Worth (2026) - GuruFocus
iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares - Stock Titan
Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants - Stock Titan
Cormorant Asset Management (IBIO) discloses 9.99% iBio stake via stock and warrants - Stock Titan
Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio - Stock Titan
iBio Inc. (IBIO) Jumps 6.79% to $1.5 as Stock Tests Key Resistance at $1.58Growth Factor - dars.gov.et
IBIO Q2 2026 Earnings: Narrower Loss and 5% Stock Pop Amid Pipeline ProgressGuidance Revision Trend - vinanet.vn
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts - MarketBeat
iBio Inc (IBIO) Stock News Today - TradingKey
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
iBio Appoints Molly Carr as Chief Medical Officer - The Globe and Mail
iBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario AS
IBIO 8-K & SEC Filings - Yahoo Finance
iBio Inc. (IBIO) Edges Higher by 2.82% as Shares Test Key Resistance ZoneATR Trailing Stop - dars.gov.et
iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan
iBio appoints Molly Carr as chief medical officer By Investing.com - Investing.com India
iBio appoints Molly Carr as chief medical officer - Investing.com
Molly Carr named Chief Medical Officer at iBio - TradingView
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Yahoo Finance
iBio Appoints Endocrinologist Molly Carr as Chief Medical Officer to Advance Obesity and Cardiometabolic Drug Pipeline – Minichart - Minichart
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):